Cytoprotection & Antioxidant Defence
BPC-157 upregulates endogenous antioxidant systems and protects hepatocyte membrane integrity. Multiple animal models show protection against alcohol-induced, NSAID-induced, and toxic liver injury.
Research Guide
Peptides for Liver Health & Detoxification
The liver performs over 500 essential functions. Research compounds with hepatoprotective, anti-fibrotic, and regenerative properties are an active area of peptide science.
BioHuman Research — Hepatic System
Research use onlySelect a structure to explore
Structure information
Select a marker on the diagram to view biological function
The liver is the largest internal organ, weighing 1.2–1.5 kg. It performs over 500 distinct biological functions including metabolism, detoxification, protein synthesis, and bile production.
Educational content only — not medical advice. For research purposes only.
How Peptides May Help
Immune Modulation
Thymosin Alpha-1 enhances T-cell-mediated viral clearance while dampening excessive inflammatory responses. It is approved in 30+ countries for chronic hepatitis B treatment.
Anti-Fibrotic Effects
Hepatic fibrosis is driven by stellate cell activation. Several peptides reduce stellate cell activation and collagen deposition in preclinical models.
Tissue Repair & Regeneration
The liver has remarkable regenerative capacity. Peptides supporting extracellular matrix remodelling and growth factor production may enhance natural recovery.
Antimicrobial Protection
In advanced liver disease, impaired immune function increases susceptibility to bacterial infections. LL-37 provides innate defence against pathogens.
Gut-Liver Axis Support
Intestinal permeability allows bacterial endotoxins to reach the liver via the portal vein. BPC-157's gut mucosal protective effects may indirectly support liver health.
Compound Research Mechanisms
Research use onlyBPC-157 — 5 mg
Indirect liver relationshipMolecular TargetVEGFR2 (vascular endothelial growth factor receptor 2); NO-synthase pathway; EGR-1 transcription factor
Liver Cell Types InvolvedHepatocytes (indirect, via gut-barrier protection); intestinal epithelial cells; endothelial cells of portal vasculature
Proposed Mechanism
BPC-157 is a synthetic pentadecapeptide derived from a gastric protein. Its proposed hepatic relevance is indirect: preclinical studies suggest it stabilises intestinal tight junctions and reduces gut permeability, thereby limiting the translocation of bacterial endotoxins (LPS) into the portal circulation. Reduced portal LPS load may attenuate Kupffer cell activation and downstream hepatic inflammatory signalling (NF-κB, TNF-α). Separate animal studies report upregulation of endogenous antioxidant defences (SOD, catalase) in hepatic tissue following toxic insult. No direct receptor binding in hepatocytes has been characterised.
Evidence by StageOverall: Preclinical only
Laboratory
In vitro studies show cytoprotective effects on cell lines exposed to oxidative stress. Mechanism of action at the molecular level remains incompletely characterised.
Animal
Multiple rodent models demonstrate protection against alcohol-induced, NSAID-induced (indomethacin, diclofenac), and CCl₄-induced hepatotoxicity. Reduced ALT/AST elevations and histological liver damage reported. (Sikiric et al., various; Stable Gastric Pentadecapeptide BPC 157 series.)
Observational Human
Evidence not established. No published observational human studies for liver-specific endpoints.
Clinical Human
Evidence not established. No completed randomised controlled trials for liver disease indications.
Key Limitation
All hepatoprotective evidence is from rodent models. The gut-liver axis mechanism is plausible but unconfirmed in humans. No pharmacokinetic data in hepatic disease populations. Extrapolation from animal data to human liver disease is not supported.
Safety / Regulatory
No approved indication for liver disease. Not evaluated in human hepatic impairment trials. Potential interactions with liver-metabolised medications are unknown. Not approved for any indication in any jurisdiction. Research compound only.
For research use only — not for human consumption. Not medical advice.
Researched Compounds
BPC-157
RecoveryHepatoprotective gastric pentadecapeptide with extensive preclinical evidence. Multiple animal studies demonstrate protection against alcohol-induced liver damage, NSAID hepatotoxicity, and toxic liver injury.
Mechanism: Cytoprotection, anti-inflammatory signalling, promotion of hepatic regeneration. Also supports the gut-liver axis through mucosal protection.
Thymosin Alpha-1
ImmuneImmunomodulator with regulatory approval in multiple countries for hepatitis treatment. Enhances T-cell-mediated antiviral responses and promotes viral clearance.
Mechanism: Immune modulation, antiviral support, hepatic immune response regulation.
Most clinically validated peptide for liver-related indications
Research compound
GHK-Cu
Skin & RepairCopper peptide for tissue repair and extracellular matrix remodelling. Stimulates collagen synthesis which may support hepatic repair following injury.
Mechanism: Anti-fibrotic potential through modulation of extracellular matrix turnover and reduction of excessive scar tissue formation.
Tesamorelin
Growth HormoneGrowth hormone-releasing hormone analogue with evidence for visceral fat and hepatic steatosis reduction in HIV-associated lipodystrophy.
Mechanism: Reduces visceral adiposity and hepatic fat content. Specific HIV indication; off-label NAFLD use not supported by Phase 3 data.
Evidence comparison
| Compound | Human Evidence | Honest Verdict |
|---|---|---|
| BPC-157 | None for liver disease | Preclinical gut-barrier/hepatoprotection signal; no human liver-disease trial |
| Thymosin Alpha-1 | Approved in 30+ countries for hepatitis B | Most clinically validated; off-label NAFLD use emerging |
| GHK-Cu | None for liver | Anti-fibrotic preclinical signal; no NAFLD/MASH trial |
| Tesamorelin | HIV-associated lipodystrophy | Specific HIV indication; off-label NAFLD unsupported by Phase 3 |
| Semaglutide/Tirzepatide | Strong (NAFLD/MASH endpoints) | Significant liver-fat reduction in trials (licensed for diabetes/obesity) |
SwissNova Labs products are supplied exclusively for laboratory research purposes. They are not intended to diagnose, treat, cure, or prevent any disease. Information on this page is educational and is not medical advice. Consult a qualified healthcare professional before making health decisions.